NCT04246372Phase 2Completed
Tofacitinib for Immune Skin Conditions in Down Syndrome
Safety and Efficacy of Tofacitinib for Immune Skin Conditions in Down Syndrome
In the register
This trial is not attached to a programme in the register yet. Unattached trials are kept on purpose: they are where new programmes turn up first.
What the registry records
- Status
- Completed
- Declared phase
- Phase 2
- Sponsor
- University of Colorado, Denver
- Participants (registry)
- 47
- Start
- October 2020
- Primary completion
- October 2024
- Study completion
- October 2024
- Last registry update
- December 2025
- Countries
- United States
Conditions studied: Down Syndrome, Alopecia Areata, Atopic Dermatitis / Eczema, Hidradenitis Suppurativa, Vitiligo, Psoriasis
Interventions: Tofacitinib, Xeljanz
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first. A registration proves a sponsor declared a study, not that it is progressing or will succeed. We're not doctors.